LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on digital health and artificial intelligence solutions for Latin America, announced today that its Venezuelan operating subsidiary, LATAMEDAI VE, has entered into an agreement with DROGUERIAS LALA C.A. to develop artificial intelligence-supported and automated software tools for pharmaceutical and laboratory operations. The collaboration aims to design, develop, test, and evaluate customized technology intended to support workflows associated with pharmaceutical research, laboratory testing, quality-control processes, documentation, operational coordination, and data analysis.
The proposed technology is expected to incorporate software tools designed to organize and analyze information generated during pharmaceutical development and laboratory activities. Planned functionality may include workflow automation, testing coordination, document management, data review, quality-control support, and predictive analytical tools intended to help qualified personnel identify potential inconsistencies or operational issues at an earlier stage. The parties will begin by identifying specific workflows to be addressed, defining the platform's technical and operational requirements, and establishing a phased development and testing process. They also intend to set up confidentiality, information-security, data-management, and access-control procedures.
The technology is designed to assist qualified personnel with the organization and review of information associated with pharmaceutical formulas, laboratory results, quality standards, testing procedures, and applicable approval processes. However, it will function as a decision-support and workflow-management resource and will not independently approve pharmaceutical formulas, laboratory results, medical products, or regulatory submissions. All pharmaceutical, scientific, laboratory, or quality-control determinations will remain the responsibility of appropriately qualified professionals and regulatory authorities.
Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI, stated, "This agreement represents an opportunity to apply our artificial intelligence and automation capabilities within complex pharmaceutical and laboratory environments. Our objective is to work with DROGUERIAS LALA C.A. to develop responsible technology that supports data analysis, documentation, testing coordination, quality-control processes, and other operational requirements while preserving appropriate professional oversight."
Management believes the collaboration may provide an opportunity to expand LataMed AI's technology into enterprise pharmaceutical and laboratory applications beyond its patient-facing telemedicine services. The initiative aligns with the company's broader strategy of developing digital infrastructure and AI-supported tools for healthcare providers, pharmacies, laboratories, institutions, and other ecosystem participants. If successfully developed and implemented, the resulting technology may provide a framework that could potentially be adapted for other organizations in Venezuela and Latin America, subject to separate agreements, successful testing, operational readiness, and regulatory requirements.
The parties will also evaluate ownership, licensing, permitted use, and protection of any intellectual property developed through the collaboration. The agreement establishes the framework for development and evaluation but does not guarantee a specific implementation schedule, commercial deployment, cost reductions, scientific outcomes, revenue, or expansion. LataMed AI will provide additional information as development progresses.
This partnership underscores the growing trend of integrating AI into pharmaceutical and laboratory settings, potentially improving efficiency and accuracy in critical workflows. For more information, visit https://latamed.ai or review the company's SEC filings at www.sec.gov.
